诊断前列腺癌的最低前列腺特异性抗原（PSA）水平。
Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
作者信息
Yesner R, Kelly L J, Chan Y K
机构信息
Yale Medical School, New Haven, USA.
出版信息
Conn Med. 1996 Jul;60(7):399-404.
The PSA levels in benign prostatic hyperplasia (BPH) and prostate adenocarcinoma (PA) overlap, both below and above 4 to 10 ng/mL. There is no known PSA level diagnostic of PA. In this study, data were obtained in 160 consecutive men aged 58 to 87. Prebiopsy PSA levels (PSA-1) were obtained prior to "sextant" gun biopsies in 97 cases diagnosed as noncarcinoma, and in 56 cases diagnosed as PA. Multiple hematoxylin and eosin sections were made of each biopsy, and Gleason scores given the PAs. Cases were followed up to 30 months with repeated PSA levels and additional biopsies. The highest PSA level in NPA in this series was 54.6 ng/mL.
良性前列腺增生（BPH）和前列腺腺癌（PA）患者的前列腺特异性抗原（PSA）水平存在重叠，在4至10 ng/mL上下均有。目前尚无已知的可诊断PA的PSA水平。在本研究中，连续纳入了160名年龄在58至87岁的男性。在97例诊断为非癌以及56例诊断为PA的患者中，于“六分法”穿刺活检前获取了活检前PSA水平（PSA-1）。对每次活检制作了多个苏木精和伊红切片，并对PA给出了Gleason评分。对病例进行了长达30个月的随访，期间重复检测PSA水平并进行了额外活检。本系列中NPA（非癌）的最高PSA水平为54.6 ng/mL。
Zotero 插件